403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
$3.3+ Billion Wound Care Biologics Market By 2032 As 130M U.S. Adults Face Diabetes Risks, CAGR Of 6.1%
(MENAFN- EIN Presswire)
Get a Sample Copy of this Report:
Key Market Drivers
.Increasing Prevalence of Chronic Wounds: The rise in chronic conditions, such as diabetic foot ulcers, is a major growth driver. As of 2022, 130 million adults in the U.S. were living with diabetes or prediabetes, leading to an increased demand for biologic-based wound care solutions.
.Advances in Wound Care Technology: New biologic-based therapies, including growth factors, tissue-engineered products, and extracellular vesicles, are improving healing outcomes. For instance, Osiris Therapeutics' Grafix product, containing growth factors and an extracellular matrix, supports better wound recovery.
.Aging Population: The elderly are more prone to chronic wounds due to thinner skin, reduced mobility, and slower healing times. As the global population ages, demand for wound care biologics is expected to grow.
Challenges Facing the Market
.High Cost of Biologics: The complex production and development of biologic therapies lead to higher costs compared to traditional wound care, limiting accessibility and adoption, especially in lower-income regions.
.Lack of Awareness: Insufficient education about biologic treatments contributes to underutilization, hindering market growth.
Segmental Overview
.By Product: The biological skin substitutes segment dominated the market in 2022, driven by increased chronic wounds and advancements in biotechnology and tissue engineering.
.By Wound Type: The chronic wound segment led in 2022 due to the rising incidence of chronic diseases like diabetes and the demand for effective wound care solutions.
.By End User: Hospitals and clinics were the largest end users in 2022, benefiting from specialized infrastructure, centralized procurement, and reimbursement support.
Regional Insights
.North America: Leading the market in 2022, North America benefited from a well-established healthcare infrastructure, major market players, and high adoption of advanced wound care biologics.
.Asia-Pacific: Expected to experience the highest growth rate due to rising healthcare infrastructure, increasing prevalence of chronic diseases, and growing awareness of biologic therapies. Countries like China and India offer significant market opportunities due to their large populations and rising healthcare investments.
Competitive Landscape
Key players in the market include Smith & Nephew, Integra LifeSciences, Bioventus, and MiMedx Group, Inc. Companies are focusing on product launches, acquisitions, and strategic agreements to strengthen their market position.
Recent Developments
.Product Launches: MiMedx launched AXIOFILL and AMNIOEFFECT in September 2022, both derived from human placental tissue to aid wound healing.
.Acquisitions: In March 2022, Convatec Group completed the acquisition of Triad Life Sciences, expanding their portfolio of advanced wound care products.
The global wound care biologics market is poised for substantial growth, driven by technological advancements, rising prevalence of chronic wounds, and an aging population. However, cost barriers and lack of awareness need to be addressed to fully capitalize on emerging market opportunities, especially in regions like Asia-Pacific.
Enquire Before Buying:
Wound Care Biologics Market size, share, demand, growth
PORTLAND, OR, UNITED STATES, October 24, 2024 /EINPresswire / -- The global wound care biologics market was valued at $1.8 billion in 2022 and is projected to reach $3.3 billion by 2032, with a CAGR of 6.1% from 2023 to 2032. Wound care biologics encompass advanced therapies derived from living organisms, such as human cells or animal tissues, that aid in wound healing, tissue regeneration, and closure. These products are especially useful in treating conditions like diabetic foot ulcers, venous leg ulcers, pressure ulcers, and various surgical and accidental wounds.Get a Sample Copy of this Report:
Key Market Drivers
.Increasing Prevalence of Chronic Wounds: The rise in chronic conditions, such as diabetic foot ulcers, is a major growth driver. As of 2022, 130 million adults in the U.S. were living with diabetes or prediabetes, leading to an increased demand for biologic-based wound care solutions.
.Advances in Wound Care Technology: New biologic-based therapies, including growth factors, tissue-engineered products, and extracellular vesicles, are improving healing outcomes. For instance, Osiris Therapeutics' Grafix product, containing growth factors and an extracellular matrix, supports better wound recovery.
.Aging Population: The elderly are more prone to chronic wounds due to thinner skin, reduced mobility, and slower healing times. As the global population ages, demand for wound care biologics is expected to grow.
Challenges Facing the Market
.High Cost of Biologics: The complex production and development of biologic therapies lead to higher costs compared to traditional wound care, limiting accessibility and adoption, especially in lower-income regions.
.Lack of Awareness: Insufficient education about biologic treatments contributes to underutilization, hindering market growth.
Segmental Overview
.By Product: The biological skin substitutes segment dominated the market in 2022, driven by increased chronic wounds and advancements in biotechnology and tissue engineering.
.By Wound Type: The chronic wound segment led in 2022 due to the rising incidence of chronic diseases like diabetes and the demand for effective wound care solutions.
.By End User: Hospitals and clinics were the largest end users in 2022, benefiting from specialized infrastructure, centralized procurement, and reimbursement support.
Regional Insights
.North America: Leading the market in 2022, North America benefited from a well-established healthcare infrastructure, major market players, and high adoption of advanced wound care biologics.
.Asia-Pacific: Expected to experience the highest growth rate due to rising healthcare infrastructure, increasing prevalence of chronic diseases, and growing awareness of biologic therapies. Countries like China and India offer significant market opportunities due to their large populations and rising healthcare investments.
Competitive Landscape
Key players in the market include Smith & Nephew, Integra LifeSciences, Bioventus, and MiMedx Group, Inc. Companies are focusing on product launches, acquisitions, and strategic agreements to strengthen their market position.
Recent Developments
.Product Launches: MiMedx launched AXIOFILL and AMNIOEFFECT in September 2022, both derived from human placental tissue to aid wound healing.
.Acquisitions: In March 2022, Convatec Group completed the acquisition of Triad Life Sciences, expanding their portfolio of advanced wound care products.
The global wound care biologics market is poised for substantial growth, driven by technological advancements, rising prevalence of chronic wounds, and an aging population. However, cost barriers and lack of awareness need to be addressed to fully capitalize on emerging market opportunities, especially in regions like Asia-Pacific.
Enquire Before Buying:
David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment